Evaluation of clinical and radiographic outcome of premixed injectable mineral trioxide aggregate and conventional mineral trioxide aggregate as pulpotomy medicaments in primary molars – A split-mouth randomized control trial
Journal of Indian Society of Pedodontics and Preventive Dentistry · 2025
DOI: 10.4103/jisppd.jisppd_373_25 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Indian Society of Pedodontics and Preventive Dentistry, 2025. Verfasst von U S Aiswarya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Preventive Dentistry, Yenepoya Dental College and Hospital, Mangalore, Karnataka, India. Hauptthemen laut MEDLINE: Calcium Compounds, Aluminum Compounds, Silicates, Oxides. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Materials for pulpotomy have evolved to materials which can regenerate the pulp. Mineral trioxide aggregate (MTA) potentially shifts the pulpal status and promotes dentin bridge formation. Newer MTAs in premixed form are resistant to dislodgment providing excellent sealability. Premixed Injectable MTA can be directly applied on the pulpal stumps promoting ease of workability and patient convenience. Aim and Objectives: To evaluate and compare the clinical and radiographic outcome of premixed injectable MTA and conventional MTA as pulpotomy medicaments in primary teeth. Materials and Methods: Thirty teeth requiring pulpotomy from 15 subjects aged between 5 and 9 years were included. After LA administration and rubber dam application, the access cavity was prepared and the coronal pulp was amputated. Premixed injectable MTA (Endocem) was applied on the pulpal stumps in one side and conventional MTA was mixed and placed on the pulpal stumps on the other side. Glass ionomer restoration was done and stainless-steel crowns were given. Clinical and radiographic follow-up was done at 3 and 6 months.
Results
At 3 months, a 100% success rate was observed in Endocem and Angelus group, clinically and radiographically. At 6 months’ follow-up, clinical success was seen in 86.67% in Angelus group and 93.33% in Endocem group. Radiographic success was seen in 86.67% in Angelus and 93.33% of Endocem group. The success rate was greater in Endocem group than Angelus group but was not statistically significant.
Conclusion
Premixed Endocem MTA can be a better alternative to conventional MTA for pulpotomy with better handling properties and faster setting time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric and Preventive Dentistry, Yenepoya Dental College and Hospital, Mangalore, Karnataka, India.
Zitieren
APA
Aiswarya, U. S., Sargod, S. S., Hegde, S. K., Rao, H. T. A., & Hegde, N. (2025). Evaluation of clinical and radiographic outcome of premixed injectable mineral trioxide aggregate and conventional mineral trioxide aggregate as pulpotomy medicaments in primary molars – A split-mouth randomized control trial. Journal of Indian Society of Pedodontics and Preventive Dentistry. https://doi.org/10.4103/jisppd.jisppd_373_25
Vancouver
Aiswarya US, Sargod SS, Hegde SK, Rao HTA, Hegde N. Evaluation of clinical and radiographic outcome of premixed injectable mineral trioxide aggregate and conventional mineral trioxide aggregate as pulpotomy medicaments in primary molars – A split-mouth randomized control trial. Journal of Indian Society of Pedodontics and Preventive Dentistry. 2025. doi:10.4103/jisppd.jisppd_373_25
BibTeX
@article{Aiswarya2025,
author = {Aiswarya, U S and Sargod, Sharan S and Hegde, Sundeep K and Rao, H T Ajay and Hegde, Nanditha},
title = {Evaluation of clinical and radiographic outcome of premixed injectable mineral trioxide aggregate and conventional mineral trioxide aggregate as pulpotomy medicaments in primary molars – A split-mouth randomized control trial},
journal = {Journal of Indian Society of Pedodontics and Preventive Dentistry},
year = {2025},
doi = {10.4103/jisppd.jisppd_373_25}
}
EUVIMED